New research is shedding light on a potential breakthrough for diagnosing Parkinson's disease (PD). A study using surface-based fluorescence intensity distribution analysis (sFIDA) found that α-synuclein aggregates, commonly associated with PD, can be detected in urine samples.

The FDA has approved the first blood test to assist in diagnosing Alzheimer's.

A recent study of over 42K participants published in Neurology reveals that a diet high in ultraprocessed foods may increase the likelihood of developing early signs of Parkinson’s disease, including probable RBD. Participants who ate the most ultraprocessed foods were 2.5 times more likely to show early symptoms like constipation, reduced smell, and sleep disturbances. While the findings aren’t conclusive, they underscore the importance of diet in brain health.

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts.

The diagnosis of REM sleep behavior disorder needs, in addition to dream enactment behavior, a determination that EMG activity is excessive during REM sleep. But what is excessive? In this podcast, the team discusses how a practicing polysomnographer can make this determination.

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts. In this podcast, the team explores ethics and empathy.

Dr. Carlos Schenck, who, alongside Mark Mahowald, was the first to describe RBD, continues to play an active role in the field, currently serving on the NAPS Scientific Advisory Board. In a recent publication in the Journal of Sleep Research, he reviewed key milestones in RBD and synucleinopathy research and discussed the current research priorities.

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts. They explore the connection between RBD and synucleinopathies like Parkinson's disease.

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts. They explore the connection between RBD and synucleinopathies like Parkinson's disease.

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts. They explore the connection between RBD and synucleinopathies like Parkinson's disease.

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts. They explore the connection between RBD and synucleinopathies like Parkinson's disease.

🧠 Exciting news in neuroscience! 🧠

Dr. Ron Postuma and colleagues have co-authored a groundbreaking study in Nature Communications.

The annual International Lewy Body Disease Congress meeting took place in Amsterdam in January 2025.

Dr. Elizabeth Coon talks with Dr. Mitchell G. Miglis about the frequency of orthostatic hypotension in isolated REM Sleep Behavior Disorder.

Exciting new research led by Dr. Kejal Kantarci, co-leader of the NAPS Neuroimaging Core, at Mayo Clinic.

Her study on FDG-PET brain imaging has uncovered crucial insights into brain metabolism changes during mild cognitive impairment.

NAPS members from McGill University, led by NAPS Co-Principal Investigator, Ron Postuma, have published a groundbreaking study in Brain journal!

NAPS Consortium Member Dr. Wolfgang Singer has been promoted to Professor of Neurology at the Mayo Clinic College of Medicine and Science.

Dr. Jeff Ratliff talks with Dr. Ron Postuma about the clinical features associated with IGLON5 positivity, emphasizing the implications for practitioners in diagnosing and treating sleep and movement disorders.

A recent publication from a large RBD cohort in Spain examined postmortem brain tissue from individuals who had RBD. This study showed there was abnormal synuclein in the cells that control atonia (muscle paralysis) during REM sleep in all the participants.